Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 11:39:32 2024-04-25 am EDT 5-day change 1st Jan Change
91.62 EUR +4.47% Intraday chart for Sanofi +7.50% +2.07%
Sales 2024 * 46.22B 49.53B Sales 2025 * 49.72B 53.28B Capitalization 110B 117B
Net income 2024 * 7.34B 7.87B Net income 2025 * 8.62B 9.24B EV / Sales 2024 * 2.52 x
Net Debt 2024 * 6.97B 7.47B Net Debt 2025 * 2.75B 2.95B EV / Sales 2025 * 2.26 x
P/E ratio 2024 *
15 x
P/E ratio 2025 *
12.8 x
Employees 86,088
Yield 2024 *
4.39%
Yield 2025 *
4.64%
Free-Float 87.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.47%
1 week+7.50%
Current month+0.73%
1 month+2.20%
3 months-0.07%
6 months-9.31%
Current year+2.07%
More quotes
1 week
85.07
Extreme 85.07
92.56
1 month
85.07
Extreme 85.07
92.56
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
105.18
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 39 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 64 20-05-21
Director/Board Member 52 20-04-27
More insiders
Date Price Change Volume
24-04-25 91.62 +4.47% 3 378 063
24-04-24 87.7 -1.29% 1,576,217
24-04-23 88.85 +0.77% 1,062,952
24-04-22 88.17 +1.47% 1,454,519
24-04-19 86.89 +1.95% 1,871,390

Real-time Euronext Paris, April 25, 2024 at 11:39 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
87.7 EUR
Average target price
107.8 EUR
Spread / Average Target
+22.87%
Consensus